Core Laboratories N.V. (NYSE:CLB) is being projected to post an EPS of $0.37 for the quarter ended 2016-09-30. 7 days ago the estimate stood at $0.37 and 30 days ago at $0.37. Similarly, the projected figure 60 days ago was $0.37 and 90 days ago it was $0.37.
The estimates have seen a change of 0% from 7 days ago. During this period, the figure was upwards 0 times and downwards 0 times. During the last 180 days upwards revision in the EPS estimate happened 0 times and downwards revision happened 3 times.
The number of revisions upwards was 0 in 30 days, 1 in 60 days, 0 in 90 days and 0 in 120 days.
The number of revisions downwards was 1 in the last 30 days, 2 in the last 60 days, 2 in the last 90 days and 3 in the last 120 days.
For the quarter ended 1, Core Laboratories N.V. (NYSE:CLB) had a mean EPS estimate of $0.37 out of 5 estimates. When the actual figure was announced on 2016-04-20 it was $0.37, giving a surprise margin of $0 or 0% per share. The actual EPS yielded a standard deviation of 0.02 from all estimates.
Quarterly Sales Estimates
2 analysts gave Core Laboratories N.V. (NYSE:CLB) an annual sales estimate of $160.1, if the arithmetic mean of the estimates is considered. The estimate stands at $160.1 if the median is considered. The estimates are for the year 2017. The estimates range from a low of $158.6 to a high of $161.6, with the standard deviation of the estimates being 2.121%.
In the last week, 2 analysts increased their sales estimate while 2 decreased it. The change in the mean estimate for the period is 0%.
In the last month, 2 analysts increased their sales estimate while 2 decreased it. The change in the mean estimate for the period is 0%.
In last 3 months, 2 analysts increased their sales estimate while 2 decreased it. The change in the mean estimate for the period is -9.955%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...